Loading…
Cardiff Oncology, Inc. is projected to decline to $1.80 by 2027, a 0% move from its current price of $1.81. CRDF is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.75 | $1.81 | $1.87 | -0.03% |
| May 30 | $1.72 | $1.81 | $1.90 | -0.06% |
| May 31 | $1.70 | $1.81 | $1.92 | -0.09% |
| Jun 1 | $1.69 | $1.81 | $1.94 | -0.12% |
| Jun 2 | $1.67 | $1.81 | $1.95 | -0.15% |
| Jun 3 | $1.66 | $1.81 | $1.97 | -0.18% |
| Jun 4 | $1.65 | $1.81 | $1.98 | -0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.65 | $1.81 | $1.98 | -0.21% |
| Week 2 | $1.58 | $1.80 | $2.05 | -0.42% |
| Week 3 | $1.53 | $1.80 | $2.11 | -0.63% |
| Week 4 | $1.49 | $1.79 | $2.16 | -0.84% |
| Week 5 | $1.46 | $1.79 | $2.20 | -1.05% |
| Week 6 | $1.43 | $1.79 | $2.24 | -1.25% |
| Week 7 | $1.40 | $1.78 | $2.27 | -1.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company that develops novel therapies for the treatment of various cancers in the United States.
Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer.
The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF is a healthcare company currently trading with a price of $1.78 and a market cap of $121.7M, ranking 4137. The near- to mid-term price outlook shows a path from a neutral stance in the mid-2020s to a bullish trajectory later, with the forecasted average price rising from $1.78 in 2026 to $2.47 by 2030 and up to $8.80 by 2050, with a potential max of $16.55 in 2050.
A major floor 20.3% below — a decisive break under it would weaken the trend.
The nearest floor, 11.6% below — buyers have tended to step in here.
The nearest ceiling, 7.2% above — a clean break opens room to run.
A major ceiling 64.1% above — clearing it would confirm fresh momentum.
Key CRDF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRDF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.83 | Sell | $1.82 | Sell |
| MA 10 | $1.77 | Buy | $1.78 | Buy |
| MA 20 | $1.71 | Buy | $1.74 | Buy |
| MA 50 | $1.69 | Buy | $1.75 | Buy |
| MA 100 | $1.91 | Sell | $1.88 | Sell |
| MA 200 | $2.09 | Sell | $2.14 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.95 | Neutral |
| Stoch RSI (14) | 52.30 | Neutral |
| CCI (20) | 95.31 | Neutral |
| Williams %R (14) | -38.24 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 10.37 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 61.76 | Neutral |
| TRIX (15) | 0.14 | Buy |
| Awesome (5,34) | 0.13 | Buy |
| Ultimate (7,14,28) | 60.50 | Neutral |
| Momentum (10) | 0.17 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 1.88 | Sell |
| ADX (14) | 10.82 | Neutral |
| ATR (14) | 0.06 | Info |
Near-term technicals show a bullish sentiment. The RSI14 is 60, and the stock trades around key moving averages with SMA50 at $1.69 and SMA200 at $2.09. Support is at $1.59 and resistance at $1.84, outlining a modest trading range ahead of the next move.
The 30-day range is $1.48 to $2.15, indicating a degree of near-term volatility. Annualized volatility sits at 50%, reflecting substantial movement potential within the month and aligning with a higher-risk, higher-variance profile for this small-cap healthcare name.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.48 | $1.81 | $2.22 | 0% | Neutral | |
| $1.39 | $1.80 | $2.50 | 0% | Neutral | |
| $1.33 | $1.78 | $2.57 | -2% | Neutral | |
| $1.63 | $2.25 | $3.37 | +24% | Bullish | |
| $1.82 | $2.58 | $3.97 | +43% | Bullish | |
| $1.86 | $2.71 | $4.28 | +50% | Bullish | |
| $2.03 | $3.03 | $4.89 | +67% | Bullish | |
| $1.79 | $2.73 | $4.49 | +51% | Bullish | |
| $1.75 | $2.72 | $4.57 | +50% | Bullish | |
| $2.08 | $3.30 | $5.63 | +82% | Bullish | |
| $2.61 | $4.55 | $8.36 | +152% | Bullish | |
| $4.61 | $9.49 | $19.33 | +424% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.48 | $1.81 | $2.14 | +0.00% |
| June 2026 | $1.52 | $1.79 | $2.17 | -1.07% |
| July 2026 | $1.47 | $1.76 | $2.17 | -1.65% |
| August 2026 | $1.50 | $1.80 | $2.25 | +2.27% |
| September 2026 | $1.47 | $1.78 | $2.25 | -1.27% |
| October 2026 | $1.38 | $1.68 | $2.14 | -5.52% |
| November 2026 | $1.36 | $1.67 | $2.14 | -0.78% |
| December 2026 | $1.39 | $1.71 | $2.22 | +2.78% |
Click any year to see its month-by-month CRDF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CRDF to range from $1.48 to $2.22 through 2026. The $1.81 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CRDF price prediction for 2027 points to an average of $1.80 (low $1.39, high $2.50) — a potential decline of 0% on today's $1.81. A consolidation phase looks the most probable path here.
In 2028, CRDF is projected to trade between $1.33 and $2.57, averaging $1.78 — a potential decline of -2% from today's $1.81. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
Cardiff Oncology, Inc.'s 2029 outlook centres on $2.25, within a $1.63 to $3.37 range. That is up +27% on the projected 2028 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CRDF could reach as high as $3.97, with a base case around $2.58 and support toward $1.82 — roughly +43% from $1.81. Momentum favours further upside here.
Expect CRDF to range from $1.86 to $4.28 through 2031. The $2.71 average target implies a +50% move from current prices. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CRDF price prediction for 2032 points to an average of $3.03 (low $2.03, high $4.89) — a potential gain of +67% on today's $1.81. Momentum favours further upside here.
In 2033, CRDF is projected to trade between $1.79 and $4.49, averaging $2.73 — a potential gain of +51% from today's $1.81. That is -10% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Cardiff Oncology, Inc.'s 2034 outlook centres on $2.72, within a $1.75 to $4.57 range. That is 0% versus the projected 2033 average. That marks a +50% change versus current levels. Momentum favours further upside here.
By 2035, CRDF could reach as high as $5.63, with a base case around $3.30 and support toward $2.08 — roughly +82% from $1.81. Buyers look set to stay in control over this stretch.
Expect CRDF to range from $2.61 to $8.36 through 2040. The $4.55 average target implies a +152% move from current prices. That is up +38% on the projected 2035 average. Momentum favours further upside here.
The CRDF price prediction for 2050 points to an average of $9.49 (low $4.61, high $19.33) — a potential gain of +424% on today's $1.81. Buyers look set to stay in control over this stretch.
Investing $1,000 in CRDF today (≈ 552.486188 CRDF) could be worth
$5,241.41
+$4,241.41 (+424%) by 2050 · US Dollar
Based on the average projected CRDF price of $9.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRDFwould be worth at today's price.
$1,000 invested in CRDF on May 27, 2025 (≈ 322.580655 CRDF) would be worth
$583.87
-$416.13 (-41.6%) today · 0.58× · US Dollar
Based on a CRDF entry price of $3.1 vs. today's $1.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.84 | $983.7 | -1.6% |
| 1 month ago | $1.72 | $1,052.33 | +5.2% |
| 3 months ago | $1.96 | $923.47 | -7.7% |
| 6 months ago | $2.28 | $793.86 | -20.6% |
| 1 year ago | $3.1 | $583.87 | -41.6% |
| All time (5.0y) ago | $8.06 | $224.57 | -77.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRDF forecast.
Our base-case forecast reaches $3.60 around 2040.
Implied market cap at $3.60: $246.13M
The multi-year forecast shows a bullish tilt developing from 2029 onward, with several years expecting meaningful upside. The 2030 forecast has an average price of $2.47 and a max of $3.64, for an implied ROI of 38.8% and a bullish sentiment. By 2040 the average is projected to reach $4.38 with a max of $7.51, yielding an estimated ROI of 145.9% and a bullish stance.
By 2050 the forecast points to an average price of $8.80 and a max of $16.55, with an implied ROI of 394.3% and a bullish sentiment. These figures illustrate a steady uptrend in the later years, along with a broad potential upside range (min to max) across the horizon. While the outlook shows substantial upside, it also implies notable volatility and uncertainty inherent in high-growth, clinical-stage equities.
The forecasts are estimates tied to projected paths and should be viewed as indicative rather than guaranteed. The data include a wide spread between min and max values and a high volatility level (50%), underscoring the potential for sizeable swings in value over time.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.47 with a min of $1.81 and a max of $3.64, and an ROI of 38.8% with a bullish sentiment.
Near-term sentiment is Neutral for 2026–2028, turning Bullish from 2029 onward. The stock has a current price of $1.78 and a market cap of $121.7M, with later years showing meaningful upside potential in the forecast (e.g., avg $2.47 by 2030 and $8.80 by 2050), but it also carries high volatility (annualized volatility 50%).
Yes. The forecast shows a max of $5.13 in 2035, indicating the possibility of reaching or exceeding $5 by that year, with higher upside in later years (e.g., $7.51 max by 2040 and $16.55 max by 2050).
Current price is $1.78 and market cap is $121.7M.
The 30-day range is $1.48 to $2.15, with RSI14 at 60, SMA50 at $1.69, SMA200 at $2.09, support at $1.59 and resistance at $1.84. The annualized volatility is 50%.
Cardiff Oncology, Inc. Community Discussion
0Share your Cardiff Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.